MBX (MBX Biosciences) Volatility: 67.49% (As of Jun. 26, 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $50.41
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Volatility?

MBX Biosciences MBX +4.07% 12 Volatility is 67.49% as of Jun. 26, 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-26), MBX Biosciences's Volatility is 67.49%.

MBX Biosciences  (NAS:MBX) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

MBX Biosciences Volatility Related Terms

MBX vs ARDX, INBX, MAZE: Volatility Comparison

For the Biotechnology subindustry, MBX Biosciences's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Volatility distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Volatility falls into.


MBX
12GF Score
MBX Biosciences Inc MBX
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences  (NAS:MBX) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 67.49% mean?
MBX Biosciences (MBX) has a Volatility of 67.49% as of Jun. 26, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on MBX Biosciences and its competitors.
Is MBX Biosciences' Volatility too high?
MBX Biosciences' current Volatility is 67.49%. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Volatility compare to ARDX and INBX?
MBX Biosciences' Volatility of 67.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current Volatility is 67.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Volatility of 67.49%. The current Volatility is 67.49%. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Volatility is 67.49% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.41
Price